|
1
|
Lan F, Nottke AC and Shi Y: Mechanisms
involved in the regulation of histone lysine demethylases. Curr
Opin Cell Biol. 20:316–325. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Prusevich P, Kalin JH, Ming SA, Basso M,
Givens J, Li X, Hu J, Taylor MS, Cieniewicz AM, Hsiao PY, et al: A
selective phenelzine analogue inhibitor of histone demethylase
LSD1. ACS Chem Biol. 9:1284–1293. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Amente S, Milazzo G, Sorrentino MC,
Ambrosio S, Di Palo G, Lania L, Perini G and Majello B:
Lysine-specific demethylase (LSD1/KDM1A) and MYCN cooperatively
repress tumor suppressor genes in neuroblastoma. Oncotarget.
6:14572–14583. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lv T, Yuan D, Miao X, Lv Y, Zhan P, Shen X
and Song Y: Over-expression of LSD1 promotes proliferation,
migration and invasion in non-small cell lung cancer. PLoS One.
7:e350652012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Huang Z, Li S, Song W, Li X, Li Q, Zhang
Z, Han Y, Zhang X, Miao S, Du R, et al: Lysine-specific demethylase
1 (LSD1/KDM1A) contributes to colorectal tumorigenesis via
activation of the Wnt/β-catenin pathway by down-regulating
Dickkopf-1 (DKK1) [corrected]. PLoS One. 8:e700772013. View Article : Google Scholar
|
|
6
|
Ketscher A, Jilg CA, Willmann D, Hummel B,
Imhof A, Rüsseler V, Hölz S, Metzger E, Müller JM and Schüle R:
LSD1 controls metastasis of androgen-independent prostate cancer
cells through PXN and LPAR6. Oncogenesis. 3:e1202014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang Y, Zhang H, Chen Y, Sun Y, Yang F, Yu
W, Liang J, Sun L, Yang X, Shi L, et al: LSD1 is a subunit of the
NuRD complex and targets the metastasis programs in breast cancer.
Cell. 138:660–672. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Si W, Huang W, Zheng Y, Yang Y, Liu X,
Shan L, Zhou X, Wang Y, Su D, Gao J, et al: Dysfunction of the
reciprocal feedback loop between GATA3- and zEB2-nucleated
repression programs contributes to breast cancer metastasis. Cancer
Cell. 27:822–836. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Singh MM, Manton CA, Bhat KP, Tsai WW,
Aldape K, Barton MC and Chandra J: Inhibition of LSD1 sensitizes
glioblastoma cells to histone deacetylase inhibitors. Neuro Oncol.
13:894–903. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li M, Chen D, Shiloh A, Luo J, Nikolaev
AY, Qin J and Gu W: Deubiquitination of p53 by HAUSP is an
important pathway for p53 stabilization. Nature. 416:648–653. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Brooks CL, Li M, Hu M, Shi Y and Gu W: The
p53-Mdm2-HAUSP complex is involved in p53 stabilization by HAUSP.
Oncogene. 26:7262–7266. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Saridakis V, Sheng Y, Sarkari F, Holowaty
MN, Shire K, Nguyen T, Zhang RG, Liao J, Lee W, Edwards AM, et al:
Structure of the p53 binding domain of HAUSP/USP7 bound to
Epstein-Barr nuclear antigen 1 implications for EBV-mediated
immortalization. Mol Cell. 18:25–36. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Song MS, Salmena L, Carracedo A, Egia A,
Lo-Coco F, Teruya-Feldstein J and Pandolfi PP: The
deubiquitinylation and localization of PTEN are regulated by a
HAUSP-PML network. Nature. 455:813–817. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Maertens GN, El Messaoudi-Aubert S,
Elderkin S, Hiom K and Peters G: Ubiquitin-specific proteases 7 and
11 modulate Polycomb regulation of the INK4a tumour suppressor.
EMBO J. 29:2553–2565. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
van der Horst A, de Vries-Smits AM,
Brenkman AB, van Triest MH, van den Broek N, Colland F, Maurice MM
and Burgering BM: FOXO4 transcriptional activity is regulated by
monoubiquitination and USP7/HAUSP. Nat Cell Biol. 8:1064–1073.
2006. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Huang Z, Wu Q, Guryanova OA, Cheng L, Shou
W, Rich JN and Bao S: Deubiquitylase HAUSP stabilizes REST and
promotes maintenance of neural progenitor cells. Nat Cell Biol.
13:142–152. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Louis DN, Ohgaki H, Wiestler OD, Cavenee
WK, Burger PC, Jouvet A, Scheithauer BW and Kleihues P: The 2007
WHO classification of tumours of the central nervous system. Acta
Neuropathol. 114:97–109. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Erpolat OP, Akmansu M, Goksel F, Bora H,
Yaman E and Büyükberber S: Outcome of newly diagnosed glioblastoma
patients treated by radiotherapy plus concomitant and adjuvant
temozolomide: A long-term analysis. Tumori. 95:191–197.
2009.PubMed/NCBI
|
|
19
|
Stupp R, Mason WP, van den Bent MJ, Weller
M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn
U, et al European Organisation for Research and Treatment of Cancer
Brain Tumor and Radiotherapy Groups; National Cancer Institute of
Canada Clinical Trials Group: Radiotherapy plus concomitant and
adjuvant temozolomide for glioblastoma. N Engl J Med. 352:987–996.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Han X, Gui B, Xiong C, Zhao L, Liang J,
Sun L, Yang X, Yu W, Si W, Yan R, et al: Destabilizing LSD1 by
Jade-2 promotes neurogenesis: An antibraking system in neural
development. Mol Cell. 55:482–494. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cheng C, Niu C, Yang Y, Wang Y and Lu M:
Expression of HAUSP in gliomas correlates with disease progression
and survival of patients. Oncol Rep. 29:1730–1736. 2013.PubMed/NCBI
|
|
22
|
Periz G, Lu J, Zhang T, Kankel MW,
Jablonski AM, Kalb R, McCampbell A and Wang J: Regulation of
protein quality control by UBE4B and LSD1 through p53-mediated
transcription. PLoS Biol. 13:e10021142015. View Article : Google Scholar : PubMed/NCBI
|
